Ceralasertib and olaparib in the treatment of homologous recombination repair (HRR)-deficient platinum-sensitive ovarian cancer after progression on PARP inhibitors
Authors
Shapiro, G. I.Basu, B.
El-Khoueiry, A.
Postel-Vinay, S.
Im, S. A.
Rha, S. Y.
Friedman, C. F.
Italiano, A.
Kim, Y. M.
Lim, M. C.
Roux, R.
Liu, J. F.
Sanai, E.
Smith, S. A.
Smith, C.
Farhi, S.
Lau, A.
Lukashchuk, N.
Dean, E.
Krebs, Matthew G
Affiliation
Dana-Farber Cancer Institute, Boston, MAIssue Date
2022
Metadata
Show full item recordCitation
Shapiro GI, Basu B, El-Khoueiry A, Postel-Vinay S, Im SA, Rha SY, et al. Ceralasertib and olaparib in the treatment of homologous recombination repair (HRR)-deficient platinum-sensitive ovarian cancer after progression on PARP inhibitors. Cancer Research. 2022 Jun;82(12). PubMed PMID: WOS:000892509502114.Journal
Cancer ResearchDOI
10.1158/1538-7445.AM2022-CT201Additional Links
https://dx.doi.org/10.1158/1538-7445.AM2022-CT201Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1158/1538-7445.AM2022-CT201